• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

为什么我们需要多功能神经保护和神经修复药物作为帕金森病和阿尔茨海默病的疾病修饰药物。

Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.

机构信息

Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Technion-Faculty of Medicine, Efron St., Haifa 31096, Israel.

出版信息

Exp Neurobiol. 2010 Jun;19(1):1-14. doi: 10.5607/en.2010.19.1.1. Epub 2010 Jun 30.

DOI:10.5607/en.2010.19.1.1
PMID:22110336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3214798/
Abstract

Parkinson's disease (PD) and Alzheimer's Disease (AD) are severe neurodegenerative disorders, with no drugs that are currently approved to prevent the neuronal cell loss characteristic in brains of patients suffering from PD and AD and all drug treatment are synptomactic. Due to the complex pathophysiology, including a cascade of neurotoxic molecular events that results in neuronal death and predisposition to depression and eventual dementia and etiology of these disorders, an innovative approach towards neuroprotection or neurorestoration (neurorescue) may be the development and use of multifunctional pharmaceuticals. Such drugs target an array of pathological pathways, each of which is believed to contribute to the cascades that ultimately lead to neuronal cell death. In this short review, we discuss examples of novel multifunctional ligands that may have potential as neuroprotective-neurorestorative therapeutics in PD and AD. The compounds discussed originate from synthetic chemistry as well as from natural sources.

摘要

帕金森病（PD）和阿尔茨海默病（AD）是严重的神经退行性疾病，目前尚无药物被批准用于预防 PD 和 AD 患者大脑中特征性的神经元细胞丢失，所有药物治疗都是对症治疗。由于复杂的病理生理学，包括一系列导致神经元死亡和易患抑郁以及最终痴呆的神经毒性分子事件级联，因此针对神经保护或神经修复（神经挽救）的创新方法可能是开发和使用多功能药物。这些药物针对一系列病理途径，每个途径都被认为有助于最终导致神经元细胞死亡的级联反应。在这篇简短的综述中，我们讨论了新型多功能配体的实例，这些配体可能具有作为 PD 和 AD 神经保护-神经修复治疗的潜力。所讨论的化合物源自合成化学和天然来源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/af1d1ed20c06/en-19-1-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/8131d5a66d87/en-19-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/44e1b423075c/en-19-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/f9bd924af17d/en-19-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/3fc250d86801/en-19-1-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/f69753864e3f/en-19-1-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/df326226c1e5/en-19-1-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/27c4a79c816b/en-19-1-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/6b6ee65b892b/en-19-1-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/e61163fe4070/en-19-1-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/ac72847e408a/en-19-1-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/af1d1ed20c06/en-19-1-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/8131d5a66d87/en-19-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/44e1b423075c/en-19-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/f9bd924af17d/en-19-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/3fc250d86801/en-19-1-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/f69753864e3f/en-19-1-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/df326226c1e5/en-19-1-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/27c4a79c816b/en-19-1-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/6b6ee65b892b/en-19-1-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/e61163fe4070/en-19-1-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/ac72847e408a/en-19-1-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0a/3214798/af1d1ed20c06/en-19-1-g011.jpg

相似文献

1
Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.为什么我们需要多功能神经保护和神经修复药物作为帕金森病和阿尔茨海默病的疾病修饰药物。
Exp Neurobiol. 2010 Jun;19(1):1-14. doi: 10.5607/en.2010.19.1.1. Epub 2010 Jun 30.
2
Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?为什么我们需要针对帕金森氏症和阿尔茨海默氏症的多功能神经保护和神经修复药物？
Rambam Maimonides Med J. 2010 Oct 31;1(2):e0011. doi: 10.5041/RMMJ.10011. Print 2010 Oct.
3
Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?为什么我们应该使用多功能神经保护和神经修复药物来治疗帕金森病？
Parkinsonism Relat Disord. 2007;13 Suppl 3:S281-91. doi: 10.1016/S1353-8020(08)70017-8.
4
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.新型多靶点神经保护和神经修复药物治疗帕金森病的前景。
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S132-6. doi: 10.1016/S1353-8020(13)70032-4.
5
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.从抗帕金森药物司来吉兰和雷沙吉兰到多功能神经保护抗阿尔茨海默病药物拉多替吉和M30的研发历程
Curr Alzheimer Res. 2006 Dec;3(5):541-50. doi: 10.2174/156720506779025288.
6
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.植物环烯醚萜类化合物在阿尔茨海默病和帕金森病中的治疗潜力：综述。
Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8.
7
Iron chelation and neuroprotection in neurodegenerative diseases.铁螯合与神经退行性疾病的神经保护。
J Neural Transm (Vienna). 2011 Mar;118(3):473-7. doi: 10.1007/s00702-010-0518-0. Epub 2010 Dec 16.
8
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.共病对使用多功能神经保护 - 神经救援药物（拉多替吉）治疗神经退行性疾病的病因及治疗的影响
Neurotox Res. 2006 Dec;10(3-4):181-92. doi: 10.1007/BF03033355.
9
A Pharmacological Appraisal of Neuroprotective and Neurorestorative Flavonoids Against Neurodegenerative Diseases.神经退行性疾病的神经保护和神经修复黄酮类化合物的药理学评价。
CNS Neurol Disord Drug Targets. 2019;18(2):103-114. doi: 10.2174/1871527317666181105093834.
10
Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy.多靶点药物在帕金森病神经修复和线粒体生物合成中的前景：干细胞治疗的替代方案
Exp Neurobiol. 2013 Sep;22(3):167-72. doi: 10.5607/en.2013.22.3.167. Epub 2013 Sep 30.

引用本文的文献

1
New Pieces for an Old Puzzle: Approaching Parkinson's Disease from Translatable Animal Models, Gut Microbiota Modulation, and Lipidomics.新拼图：从可翻译的动物模型、肠道微生物群调节和脂质组学角度探讨帕金森病。
Nutrients. 2023 Jun 16;15(12):2775. doi: 10.3390/nu15122775.
2
Brain-protective mechanisms of autophagy associated circRNAs: Kick starting self-cleaning mode in brain cells circRNAs as a potential therapeutic approach for neurodegenerative diseases.自噬相关环状RNA的脑保护机制：启动脑细胞的自我清洁模式 环状RNA作为神经退行性疾病的一种潜在治疗方法。
Front Mol Neurosci. 2023 Jan 16;15:1078441. doi: 10.3389/fnmol.2022.1078441. eCollection 2022.
3

本文引用的文献

1
MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?单胺氧化酶B抑制剂：在神经退行性疾病治疗中的多重作用？
Parkinsonism Relat Disord. 2000 Jan;6(1):25-47. doi: 10.1016/s1353-8020(99)00043-7.
2
Multi-target therapeutics: when the whole is greater than the sum of the parts.多靶点疗法：整体大于部分之和。
Drug Discov Today. 2007 Jan;12(1-2):34-42. doi: 10.1016/j.drudis.2006.11.008. Epub 2006 Nov 28.
3
Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
Exploring links between 2-oxoglutarate-dependent oxygenases and Alzheimer's disease.
探索 2-氧戊二酸依赖的加氧酶与阿尔茨海默病之间的联系。
Alzheimers Dement. 2022 Dec;18(12):2637-2668. doi: 10.1002/alz.12733. Epub 2022 Jul 19.
4
and Characterization of Kurarinone as a Dopamine D Receptor Antagonist and D and D Receptor Agonist.苦参醌作为多巴胺D受体拮抗剂以及D和D受体激动剂的表征
ACS Omega. 2021 Dec 6;6(49):33443-33453. doi: 10.1021/acsomega.1c04109. eCollection 2021 Dec 14.
5
Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress.褪黑素类似物可有效抑制单胺氧化酶B并保护PC12细胞免受氧化应激。
Antioxidants (Basel). 2021 Oct 12;10(10):1604. doi: 10.3390/antiox10101604.
6
The Emerging Role of Circular RNAs in Alzheimer's Disease and Parkinson's Disease.环状RNA在阿尔茨海默病和帕金森病中的新兴作用
Front Aging Neurosci. 2021 Jul 12;13:691512. doi: 10.3389/fnagi.2021.691512. eCollection 2021.
7
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).表没食子儿茶素-3-没食子酸酯（EGCG）的潜在神经保护特性。
Nutr J. 2016 Jun 7;15(1):60. doi: 10.1186/s12937-016-0179-4.
8
Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.γ-咔啉与吩噻嗪的缀合物作为新型丁酰胆碱酯酶选择性抑制剂和阿尔茨海默病NMDA受体阻滞剂
Sci Rep. 2015 Aug 18;5:13164. doi: 10.1038/srep13164.
9
Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism.在允许内源性药物代谢的星形胶质细胞共培养系统中预防人类多巴胺能神经元的退化。
Br J Pharmacol. 2015 Aug;172(16):4119-32. doi: 10.1111/bph.13193. Epub 2015 Jun 26.
10
Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance.转录因子 Foxa1 和 Foxa2 对于成年多巴胺神经元的维持是必需的。
Front Cell Neurosci. 2014 Sep 9;8:275. doi: 10.3389/fncel.2014.00275. eCollection 2014.
五环十一烷基胺在 N-甲基-D-天冬氨酸受体上的构效关系
Bioorg Med Chem. 2007 Feb 1;15(3):1525-32. doi: 10.1016/j.bmc.2006.09.060. Epub 2006 Sep 29.
4
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.新型脑渗透性多功能铁螯合剂-单胺氧化酶抑制剂药物M-30治疗阿尔茨海默病的治疗靶点及潜力
J Neurochem. 2007 Jan;100(2):490-502. doi: 10.1111/j.1471-4159.2006.04258.x. Epub 2006 Nov 27.
5
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.针对单胺氧化酶抑制、铁螯合、腺苷受体以及胆碱能和谷氨酸能作用的多功能神经保护药物，用于治疗神经退行性疾病。
Expert Opin Investig Drugs. 2006 Aug;15(8):873-86. doi: 10.1517/13543784.15.8.873.
6
NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels.NGP1-01是一种可透过血脑屏障的神经元电压门控性和配体门控性钙通道双重阻滞剂。
Neurochem Res. 2006 Mar;31(3):395-9. doi: 10.1007/s11064-005-9036-0.
7
Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.（-）-表没食子儿茶素-3-没食子酸酯在细胞培养物中降低铁调节的淀粉样前体蛋白和β-淀粉样肽：对阿尔茨海默病中铁螯合的影响
J Neurochem. 2006 Apr;97(2):527-36. doi: 10.1111/j.1471-4159.2006.03770.x. Epub 2006 Mar 15.
8
Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.绿茶儿茶素作为可透过血脑屏障的天然铁螯合剂-抗氧化剂用于治疗神经退行性疾病。
Mol Nutr Food Res. 2006 Feb;50(2):229-34. doi: 10.1002/mnfr.200500156.
9
Designed multiple ligands. An emerging drug discovery paradigm.设计多种配体。一种新兴的药物发现模式。
J Med Chem. 2005 Oct 20;48(21):6523-43. doi: 10.1021/jm058225d.
10
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.用于神经退行性疾病的新型多功能神经保护铁螯合剂 - 单胺氧化酶抑制剂药物。体内选择性脑单胺氧化酶抑制及预防MPTP诱导的纹状体多巴胺耗竭。
J Neurochem. 2005 Oct;95(1):79-88. doi: 10.1111/j.1471-4159.2005.03341.x.